CSI Market
Sign In | Register

Revance Therapeutics Inc (RVNC) Annual Balance Sheets

Annual · GAAP · USD millions
Access RVNC quarterly Balance Sheets →
Balance sheet performance over multiple periods helps investors evaluate the financial resilience of Revance Therapeutics Inc.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2023)
(Dec 31 2022) (Dec 31 2021) (Dec 31 2020) (Dec 31 2019)
Assets
Cash & cash equivalent137.33
Restricted Cash and Cash Equivalents, Current0.55
Short-term Investments, Total116.59
Cash & Short-term Investments253.00
Accounts receivable27.68
Inventories45.58
Prepaid Expense And Other Assets Current11.15
Total Current Assets338.87
Equipment/Property/Plant Net17.23
Goodwill net0.00
Intangible Assets9.81
Long-term investments6.87
Other Assets, Noncurrent55.00
Operating Lease Right Of Use Asset53.17
Total Assets478.45
Liabilities
Accounts Payable, Current AC13.81
Accrued Liabilities, Current AC53.82
Derivative Liability, Current DE0.00
Long-term Debt, Current Maturities LO2.50
Other Liabilities, Current19.09
Total Current Liabilities89.22
Long-term debt426.60
Convertible Notes Payable, Noncurrent LO0.00
Total Long-term Debt426.60
Other liabilities, Noncurrent114.24
Contract With Customer Liability Current10.74
Operating Lease Liability Current5.70
Contract With Customer Liability Noncurrent70.42
Total Liabilities630.06
Stockholders' Equity
Common Stock Value0.09
Additional Paid In Capital Common Stock1,926.65
Retained Earnings / Accumulated Deficit-2,078.36
Other Equity0.01
Common Stockholder's Equity-151.60
Total Stockholder's Equity-151.60
Liabilities & Stockholder's Equity478.45
4 historic quarters locked

Sign in to unlock the full Revance Therapeutics Inc balance sheet history.

Sign In Create Free Account

About Revance Therapeutics Inc Annual Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-K filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-K (Period: 20231231)
  • Filed with the SEC: February 28, 2024
  • Source: rvnc-20231231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001479290-24-000038

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API License